| Lynn H Samuel, MD | |
|
493 Blackwell Rd, Suite 101a, Warrenton, VA 20186-2628 | |
| (540) 316-5604 | |
| (540) 316-5601 |
| Full Name | Lynn H Samuel |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 36 Years |
| Location | 493 Blackwell Rd, Warrenton, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013906627 | NPI | - | NPPES |
| 6600590 | Medicaid | VA | |
| P00757523 | Other | VA | RR MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fauquier Hospital | Warrenton, VA | Hospital |
| Entity Name | Pathfinder Diagnostics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962697037 PECOS PAC ID: 1456425024 Enrollment ID: O20080730000478 |
News Archive
The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered how Alzheimer's disease damages mitochondria, the powerhouses of the cell.
Researchers from the Department of Pediatrics at Case Western Reserve University School of Medicine and University Hospitals Rainbow Babies and Children's Hospital presented results of a study that investigated whether there are any deleterious effects of prostaglandin E1 treatment on breathing and whether these effects would be prevented via pre-treatment with caffeine.
Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.
Endosense,a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study.
› Verified 1 days ago
| Entity Name | Lynn H Samuel Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053546572 PECOS PAC ID: 5294886594 Enrollment ID: O20090626000242 |
News Archive
The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered how Alzheimer's disease damages mitochondria, the powerhouses of the cell.
Researchers from the Department of Pediatrics at Case Western Reserve University School of Medicine and University Hospitals Rainbow Babies and Children's Hospital presented results of a study that investigated whether there are any deleterious effects of prostaglandin E1 treatment on breathing and whether these effects would be prevented via pre-treatment with caffeine.
Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.
Endosense,a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lynn H Samuel, MD 1560 Chapman Rd, Stanardsville, VA 22973-3620 Ph: (540) 316-5604 | Lynn H Samuel, MD 493 Blackwell Rd, Suite 101a, Warrenton, VA 20186-2628 Ph: (540) 316-5604 |
News Archive
The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered how Alzheimer's disease damages mitochondria, the powerhouses of the cell.
Researchers from the Department of Pediatrics at Case Western Reserve University School of Medicine and University Hospitals Rainbow Babies and Children's Hospital presented results of a study that investigated whether there are any deleterious effects of prostaglandin E1 treatment on breathing and whether these effects would be prevented via pre-treatment with caffeine.
Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.
Endosense,a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study.
› Verified 1 days ago
Dr. Elizabeth Stone Martin, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 500 Hospital Dr, Warrenton, VA 20186 Phone: 703-391-3654 Fax: 703-391-3049 | |
Michael M Orlando, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 500 Hospital Dr, Warrenton, VA 20186 Phone: 540-347-2550 | |
Dr. Kelly Domson, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 500 Hospital Drive, Warrenton, VA 20186 Phone: 703-257-1440 Fax: 703-257-4337 |